Diagnostic evaluation of immune low-response ovarian cancer should progress from discovery-grade single-cell and spatial assays to deployable, site-aware risk stratification that quantifies TGF-β–conditioned stromal programs, antigen-presentation deficits, and the geometry of tumor–immune contacts. The gene discussed is TGFB1; the disease is ovarian cancer.